Minoxidil therapy in children with severe hypertension. 1977

A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine

Six children, from 1.3 to 18 years of age, with severe hypertension associated with the hemolytic uremic syndrome, periarteritis, and renal transplant rejection received minoxidil, an antihypertensive agent, for three to 36 weeks. All had severe hypertension resistant to oral antihypertensive medications; five required frequent intravenous diazoxide therapy prior to minoxidil therapy. The mean pretreatment systolic and diastolic blood pressures were 176 and 117 mm Hg, respectively. Following treatment, the mean systolic and diastolic blood pressures were 133 and 82 mm Hg, respectively. Concomitant antihypertensive medications were decreased in all six patients once optimal blood pressure control was obtained. The initial dosage of minoxidil was 0.1 to 0.2 mg/kg/day; maximal dosage for blood pressure was 0.3 to 1.4 mg/kh/day. Major complications of therapy were fluid retention and hirsutism. Transient asymptomatic pericardial effusions occurred in two patients. Three patients on prolonged minoxidil therapy had persistent increases in right ventricular end diastolic diameters. Minoxidil is an effective oral antihypertensive agent for treatment of severe hypertension in pediatric patients. Avoidance of fluid retention is mandatory to prevent congestive heart failure.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008914 Minoxidil A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371) Loniten,Regaine,Rogaine,U 10858
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003981 Diazoxide A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. Hyperstat,Proglycem
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
July 1983, American journal of kidney diseases : the official journal of the National Kidney Foundation,
A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
July 1975, JAMA,
A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
January 1978, Acta medica Scandinavica,
A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
October 1983, Australian and New Zealand journal of medicine,
A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
November 1978, European journal of clinical pharmacology,
A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
October 1975, Israel journal of medical sciences,
A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
January 1981, Drug and therapeutics bulletin,
A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
January 1980, Journal of cardiovascular pharmacology,
A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
November 1982, Archives of internal medicine,
A J Pennisi, and M Takahashi, and B H Bernstein, and B H Singsen, and C Uittenbogaart, and R B Ettenger, and M H Malekzadeh, and V Hanson, and R N Fine
January 1975, Current therapeutic research, clinical and experimental,
Copied contents to your clipboard!